Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron vs Tolterodine ER in Overactive Bladder (PREFER)
NCT02138747Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of mirabegron in overactive bladder (OAB), sponsored by Astellas Pharma. Started Jul 2014; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02138747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138747.